AbbVie (ABBV) is reaffirming its expectations for a high single-digit compound annual revenue growth rate through 2029. This guidance assumes ...

Says well-positioned with ex-Humira platform for 2025. Sees clear runway for growth “for at least eight years.” Expects Skyrizi and Rinvoq to ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

In a carbon copy of 2023’s results, the 2024 list features AbbVie’s Skyrizi and Rinvoq in the top two spots, followed by yet another immunology giant, Sanofi and Regeneron’s Dupixent ...

Though it was often joined at the top of the list throughout the year by fellow AbbVie offering Rinvoq, that wasn’t the case in December, when Rinvoq fell two spots as its TV ad spending dropped ...

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody blockbuster Humira.

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

The EU regulator has cleared Rinvoq (upadacitinib) as an oral treatment for moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older, either with or without topical ...